ConductScience.org, home

Paper114397

Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.

D'Incalci M and 4 others. Eur J Drug Metab Pharmacokinet, 1979. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients. Papers, record 114397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/114397

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients.
PubMed
Journal
Eur J Drug Metab Pharmacokinet
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.17
iCite
Revised in PubMed
2018-11-13
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1D'Incalci MM
2Facchinetti TT
3Bolis GG
4Mangioni CC
5Morasca LL

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CyclophosphamideMajor topic
Ovarian NeoplasmsMajor topic
Dose-Response Relationship, Drug
Female
Half-Life
Humans
Kinetics
Long-Term Care
Pregnancy

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14479366The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects.Acta Pharmacol Toxicol (Copenh)1974https://conductscience.org/library/papers/4479366PubMed
24393764Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.J Pharmacol Exp Ther1970https://conductscience.org/library/papers/4393764PubMed
31131393Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.Biomed Mass Spectrom1975https://conductscience.org/library/papers/1131393PubMed
413700518Studies on the mechanism of action of cytoxan. Evidence of activation in vivo and in vitro.Cancer Res1961https://conductscience.org/library/papers/13700518PubMed
55570713Drug metabolism after repeated treatments with cytotoxic agents.Eur J Cancer (1965)1971https://conductscience.org/library/papers/5570713PubMed
6649726Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen--phosphorus-selective detector.J Chromatogr1978https://conductscience.org/library/papers/649726PubMed
71277205Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.Cancer Treat Rep1976https://conductscience.org/library/papers/1277205PubMed
85157730Pharmacokinetics of cyclophosphamide in man.Br J Pharmacol1971https://conductscience.org/library/papers/5157730PubMed
95014778Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite.Cancer Res1972https://conductscience.org/library/papers/5014778PubMed
104811053Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.Biochem Pharmacol1974https://conductscience.org/library/papers/4811053PubMed
11954793Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.Eur J Cancer (1965)1976https://conductscience.org/library/papers/954793PubMed
1214208670[ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].Arzneimittelforschung1963https://conductscience.org/library/papers/14208670PubMed
134397323Metabolism of cyclophosphamide by rat hepatic microsomes.Cancer Res1971https://conductscience.org/library/papers/4397323PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn Papers
23143218Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.Clin Cancer Res2013https://conductscience.org/library/papers/23143218

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/114397

GET https://conductscience.org/api/papers/v1/114397/authors